MedTrace Logo

MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations

NCT01827384 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 208

Last updated 2023-09-29

Study results available
· View outcomes & findings →

Summary

This phase II trial studies molecular profiling-based assignment of cancer therapy (MPACT) in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced). Adavosertib, everolimus, and trametinib are drugs that each target a specific variation in tumors by blocking different proteins needed for cell growth. Veliparib blocks an enzyme that helps repair deoxyribonucleic acid (DNA) damaged by chemotherapy, which may help chemotherapy drugs work better. It is not yet known whether testing patients for variations in their tumor and assigning treatment targeting the variation is more effective than standard non-targeted therapy in treating advanced solid tumors.

Conditions

  • Advanced Malignant Solid Neoplasm

Interventions

DRUG

Adavosertib

Given by mouth (PO)

DRUG

Carboplatin

Given intravenous (IV)

DRUG

Everolimus

Given by mouth (PO)

DRUG

Temozolomide

Given by mouth (PO)

DRUG

Trametinib

Given by mouth (PO)

DRUG

Veliparib

Given by mouth (PO)

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • A P Chen · National Cancer Institute LAO

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-07
Primary Completion
2021-06-19
Completion
2021-10-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01827384 on ClinicalTrials.gov